Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy

Karlo Perica, Sarah Nataraj, Maria Lemdal Sjojstrand, Katherine Nagel, Emma Pavkovic, Erica Payson, Ana Cuenca, Anjali Patel, David Chung, Sham Mailankody, Gunjan L. Shah, Saad Z Usmani, Sergio A. Giralt, Michel Sadelain

Blood (2023) 142 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2023-178954

Published: 2023

Journal Articles

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

Sanam Shahid, Georgia C Flynn, Audrey Mauguen, Jennifer Bieler, Susan E Prockop, Andromachi Scaradavou, Jaap Jan Boelens, Craig S Sauter, Miguel-Angel Perales, Sergio A. Giralt, Xiuyan Wang, Isabelle Riviere, Michel Sadelain, Renier Brentjens, Nancy A Kernan, Richard J O'Reilly, Kevin J Curran

Blood (2023) 142 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2023-180753

Published: 2023

Journal Articles

GLUT1 Overexpression Enhances 19-28z CAR-T Cell Expansion and Metabolic Fitness

Yuzhe SHI, Ivan S Kotchetkov, Sophie Alexandra Hanina, Michel Sadelain

Blood (2023) 142 (Supplement 1): 3455.

https://doi.org/10.1182/blood-2023-188417

Published: 2023

Journal Articles

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Varsha Sundaresan, Brigitte Senechal, Xiuyan Wang, Shubhra Kashyap, Erica Tong, Adarsh Joshi, Ajeeta Dash, Leopold Sellner, Sharon Chen, Devin McAvoy, Kinga K Hosszu, Devanjan S Sikder, Isabelle Riviere, Michel Sadelain, Jae H. Park, Reshma Singh

Blood (2023) 142 (Supplement 1): 349.

https://doi.org/10.1182/blood-2023-177712

Published: 2023

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain

Blood (2023) 142 (Supplement 1): 892.

https://doi.org/10.1182/blood-2023-187623

Published: 2023

Journal Articles

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Blood (2023) 142 (Supplement 1): 357.

https://doi.org/10.1182/blood-2023-174728

Published: 2023

Journal Articles

Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering

Ashlesha Odak, Han Yuan, Judith Feucht, Vito Adrian Cantu, Jorge Mansilla-Soto, Friederike Kogel, Justin Eyquem, John Everett, Frederic D. Bushman, Christina S. Leslie, Michel Sadelain

Blood (2023) 141 (22): 2698–2712.

https://doi.org/10.1182/blood.2022018924

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H Park, M. Lia Palomba, Isabelle Rivière, Devanjan S. Sikder, Brigitte Senechal, Xiuyan Wang, Vladimir P. Bermudez, Elizabeth R. Cathcart, Kelly Liotta, Jannakie Joseph, Jia Li, Yunqi Zhao, Rachael Liu, Sharon Chen, Leopold Sellner, Michel Sadelain

Blood (2022) 140 (Supplement 1): 403–404.

https://doi.org/10.1182/blood-2022-168206

Published: 2022

Journal Articles

The Development of Allogeneic Tips-Derived TCR - CAR + CD8αβ T Cells

Sjoukje J.C. van der Stegen, Roseanna M. Petrovic, Pieter L. Lindenbergh, Mame P. Diop, Vera Alexeeva, Hongyao Xie, Raedun Clarke, Bahram Valamehr, Isabelle Rivière, Michel Sadelain

Blood (2022) 140 (Supplement 1): 10290–10291.

https://doi.org/10.1182/blood-2022-169375

Published: 2022

Journal Articles

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Quirin Hammer, Karlo Perica, Rina M Mbofung, Hanna van Ooijen, Erika Varady, Mark Jelcic, Yijia Pan, Pouria Momayyezi, Brian Groff, Ramzey Abujarour, Silje Zandstra Krokeide, Tom Lee, Alan M Williams, Jode P Goodridge, Bahram Valamehr, Bjorn Onfelt, Michel Sadelain, Karl-Johan Malmberg

Blood (2022) 140 (Supplement 1): 1165–1166.

https://doi.org/10.1182/blood-2022-163086

Published: 2022

Journal Articles

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Friederike Kogel, Qing Chang, Elisa De Stanchina, Kathryn Fraser, Jae H Park, Xiuyan Wang, Isabelle Rivière, Michel Sadelain

Blood (2022) 140 (Supplement 1): 869–870.

https://doi.org/10.1182/blood-2022-162968

Published: 2022

Journal Articles

Overcoming Heterogeneity in AML with a Novel or-Gated Hitcar-1XX Platform

Sascha Haubner, Jorge Mansilla-Soto, Andreina Garcia Angus, Qing Chang, Elisa De Stanchina, Michel Sadelain

Blood (2022) 140 (Supplement 1): 865–866.

https://doi.org/10.1182/blood-2022-162579

Published: 2022

Journal Articles

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

Jae H Park, Craig S. Sauter, M. Lia Palomba, Gunjan L Shah, Parastoo B Dahi, Richard J Lin, Michael Scordo, Connie Lee Batlevi, Miguel-Angel Perales, Peter Kane, Aishat Olaide Afuye, Elena Mead, Bianca Santomasso, Elizabeth Halton, Michel Sadelain, Renier J Brentjens

Blood (2021) 138 (Supplement 1): 96.

https://doi.org/10.1182/blood-2021-150431

Published: 2021

Journal Articles

"IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy

Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Xingyue He, Jae H Park, Xiuyan Wang, Isabelle Rivière, Michel Sadelain

Blood (2021) 138 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2021-149263

Published: 2021

Journal Articles

Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances

Giulia Cheloni, Marzia Capelletti, Daniela Torres, Poorva Bindal, Jessica J. Liegel, Dina Stroopinsky, Lina Bisharat, Maryam Rahimian, Seo Yeon Yoo, Joshua Hauser, Anita G. Koshy, Kenel Dufort, John G. Clohessy, Donald Kufe, Maria Themeli, Jacalyn Rosenblatt, Michel Sadelain, David Avigan

Blood (2021) 138 (Supplement 1): 737.

https://doi.org/10.1182/blood-2021-150307

Published: 2021

Journal Articles

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 253.

https://doi.org/10.1182/blood-2021-153945

Published: 2021

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Erythroid Specificity and Safety of Globin-Encoding Lentiviral Vectors

Annalisa Cabriolu, PhD, Ashlesha Odak, MS, Friederike Kogel, MD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-142989

Published: 2020

Journal Articles

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

Sjoukje van der Stegen, PhD, Pieter Lindenbergh, Roseanna Petrovic, PhD, Benjamin Whitlock, PhD, Raedun Clarke, PhD, Bahram Valamehr, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 30.

https://doi.org/10.1182/blood-2020-142894

Published: 2020

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD, Isabelle Riviere, PhD, Devanjan S. Sikder, Vladimir P. Bermudez, Brigitte Senechal, Xiuyan Wang, PhD, Thomas H. Auchincloss, Claudia Diamonte, RN, Elizabeth Halton, NP-BC AOCNP, M. Lia Palomba, MD, Renier J. Brentjens, MD PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143088

Published: 2020

NARROW

Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory B-Cell Malignancies

GLUT1 Overexpression Enhances 19-28z CAR-T Cell Expansion and Metabolic Fitness

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The Development of Allogeneic Tips-Derived TCR - CAR + CD8αβ T Cells

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Overcoming Heterogeneity in AML with a Novel or-Gated Hitcar-1XX Platform

A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma

"IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy

Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Erythroid Specificity and Safety of Globin-Encoding Lentiviral Vectors

NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only